Remarkably, PD‐1 inhibitors demonstrated superior survival outcomes, providing valuable insights into the strategic selection of immunotherapeutic agents for lung cancer treatment, ultimately aiming to improve patient prognosis and survival rates. This evidence concerns the gene PDCD1 and lung cancer.